Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature

Cancer

Volumn 110, Issue 5, 2007, Pages 1042-1049

  Badros, Ashraf ^a   Goloubeva, Olga ^a   Dalal, Jay S ^a   Can, Ilyas ^a   Thompson, Jennifer ^a   Rapoport, Aaron P ^a   Heyman, Meyer ^a   Akpek, Gorgon ^a   Fenton, Robert G ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Bortezomib; Lenalidomide; Neuropathy; Neurotoxicity; Thalidomide

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BORTEZOMIB; CAPSAICIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DULOXETINE; ETOPOSIDE; GABAPENTIN; LENALIDOMIDE; MELPHALAN; PYRIDOXINE; THALIDOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VINCRISTINE;

ADULT; AGED; ARTICLE; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 34548183776     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22921     Document Type: Article

References (40)

1. San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11:51-61.
2. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
3. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113-3120.
4. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain. 2007;8:296-306.
5. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007;204:317-325.
6. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
7. Gidal BE. New and emerging treatment options for neuropathic pain. Am J Manag Care. 2006;12(9 suppl):S269-S278.
8. Badros A, Goloubeva O, Fenton R, et al. Phase 1 trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma. 2006;7:210-216.
9. Badros A, Gahres N. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait. Clin Adv Hematol. Oncol. 2005;3:916-917; discussion 918.
10. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004;18(14Suppl 11):14-21.
11. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006; 24:4507-4514.
12. Borrello I, Ferguson A, Huff CA, et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma - efficacy and neurotoxicity. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3528.
13. Palumbo A, Ambrosini MT, Benevolo G, et al. Combination of bortezomib, melphalan, prednisone and thalidomide (VMPT) for relapsed multiple myeloma: results of a phase I/II clinical trial. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 407.
14. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood (ASH Annual Meeting Abstracts). 2005; 106. Abstract 784.
15. Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T. Blood (ASH Annual Meeting Abstracts). 2005;106. Abstract 2552.
16. Terpos E, Anagnostopoulos A, Heath D, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of dickkopf-1, RANKL, MIP-1α and angiogenic cytokines. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3541.
17. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006;11:135-141.
18. Richardson PG, Jagannath S, Avigan DE, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 405.
19. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology. 2002;59:1872-1875.
20. Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol. 2005;18:574-580.
21. El-Cheikh J, Stoppa AM, Duran S, et al. Features and risk factors of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 5098.
22. Kaba H, Fukuda H, Yamamoto S, Ohashi Y. Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0 [in Japanese]. Gan To Kagaku Ryoho. 2004;31: 1187-1192.
23. Cocito D, Paolasso I, Pazzaglia C, et al. Pain affects the quality of life of neuropathic patients. Neurol Sci. 2006;27: 155-160.
24. Magy L. Changes in the assessment of peripheral neuropathy in the last decade [in French]. Rev Neurol (Paris). 2006;162:1279-1283.
25. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91:929-934.
26. Jackson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev. 2005;31:591-602.
27. Dispenzieri A, Zhang L, Fonseca R, Vesole DH, Greipp PR. Single agent bortezomib is associated with a high response rate in patients with high risk myeloma, a phase II study from the Eastern Cooperative Oncology Group (E2A02). Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3527.
28. Katan MB. How much vitamin B6 is toxic? [in Dutch]. Ned Tijdschr Geneeskd. 2005;149(46):2545-6.
29. Levine S, Saltzman A. Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein-deficient diet. J Appl Toxicol. 2004;24:497-500.
30. Krinke G, Schaumburg HH, Spencer PS, Suter J, Thomann R Hess R. Pyridoxine megavitaminosis produces degeneration of peripheral sensory neurons (sensory neuronopathy) in the dog. Neurotoxicology. 1981;2:13-24.
31. Catley L, Anderson KC. Velcade and vitamin C: too much of a good thing? Clin Cancer Res. 2006;12:3-4.
32. Zou W, Yue P, Lin N, et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res. 2006;12:273-280.
33. Teoh G, Tan D, Hwang W, Koh LP, Chuah C, Ng HJ. Use of immunoglobulin infusions in the management of bortezomib-induced peripheral neuropathy in multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 5097.
34. Mikhael JR, Belch A, Prince M, et al. Preliminary safety and efficacy results from an international phase 3b study for expanded access to bortezomib in 624 patients with relapsed and/or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3530.
35. Orlowski RZ, Zhuang SH, Parekh T, Xiu L, Harousseau J-L,the DOXIL-MMY-3001 Study Investigators. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 404.
36. Popat R, Williams C, Cook M, et al. A phase I/II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3542.
37. Jagannath S, Durie BGM, Wolf JL, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 796.
38. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase 11 study. Haematologica. 2006;91:1498-1505.
39. Rosinol L, Oriol A, Mateos M-V, et al. Alternating bortezomib and dexamethasone as induction regimen prior to autologous stem-cell transplantation in newly diagnosed younger patients with multiple myeloma: results of a PETHEMA phase II trial. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3086.
40. Orlowski RZ, Peterson BL, Sanford B, et al. Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Can cer and Leukemia Group B Study 10301. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 797.